Cellosaurus PC-3 (CVCL_0035)

Cell line name PC-3
Synonyms PC3; PC.3
Accession CVCL_0035
Resource Identification Initiative To cite this cell line use: PC-3 (RRID:CVCL_0035)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: JFCR39 cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Part of: NCI60 cancer cell line panel.
Doubling time: 27.1 hours (NCI-DTP); 25 hours (ATCC); ~50 hours (DSMZ).
Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).
Sequence variation: Homozygous for TP53 p.Lys139fs*31 (PubMed=8104329; PubMed=17088437).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: Glycoproteome analysis by proteomics.
Omics: GPI-anchored proteins analysis by proteomics.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Caution: There seems to be two distinct cell lines which were assigned NCBI_Iran catalog number C427.
Disease Prostate carcinoma (NCIt: C4863)
Derived from metastatic site: Bone.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_L211 (1-LN); CVCL_4735 (ALVA-101); CVCL_4737 (ALVA-31); CVCL_4734 (ALVA-41); CVCL_4736 (ALVA-55); CVCL_4738 (DuPro-1); CVCL_5989 (JHU-019); CVCL_4868 (MPC-3-10); CVCL_4Y40 (PC-3 D12); CVCL_4Y41 (PC-3 D8); CVCL_6E88 (PC-3 MC); CVCL_6E89 (PC-3 MK); CVCL_6E90 (PC-3 ML); CVCL_6E91 (PC-3 MR); CVCL_4877 (PC-3-1A); CVCL_J265 (PC-3-Luc); CVCL_5J26 (PC-3-luc2); CVCL_5J29 (PC-3-luc2-GFP); CVCL_5J08 (PC-3-Red-FLuc); CVCL_5J09 (PC-3-Red-FLuc-GFP); CVCL_M060 (PC-3/nKR); CVCL_B289 (PC-3H); CVCL_9555 (PC-3M); CVCL_4886 (PC-3N); CVCL_0482 (PC-3U); CVCL_M124 (PC-5); CVCL_X641 (PC-J); CVCL_D689 (PC3B1); CVCL_C169 (PCI-03); CVCL_4778 (PPC-1)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CLS; Cosmic-CLP; DOI=10.4172/2157-7145.S2-005; DSMZ; ECACC; JCRB; KCLB; PubMed=11416159; PubMed=14518029; PubMed=17254797; PubMed=19372543; PubMed=25877200; RCB; TKG

Markers:
AmelogeninX
CSF1PO11
D13S31711
D16S53911
D18S5114,15 (CLS; DOI=10.4172/2157-7145.S2-005; PubMed=11416159; PubMed=14518029; PubMed=19372543; PubMed=25877200)
13,14 (PubMed=17254797)
D19S43314
D21S1129,31.2 (CLS; DOI=10.4172/2157-7145.S2-005; PubMed=11416159; PubMed=14518029; PubMed=19372543; PubMed=25877200)
29,31 (PubMed=17254797)
D2S133818,20
D3S135816
D5S81813
D7S8208,11 (AddexBio; ATCC; CLS; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=14518029; PubMed=19372543; PubMed=25877200; RCB)
8 (PubMed=17254797; TKG)
D8S117913
FGA24
Penta D9
Penta E10,17
TH016,7
TPOX8,9
vWA17
Web pages https://en.wikipedia.org/wiki/PC3
https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://strap.nci.nih.gov/celline_detail.php?sample_id=53
http://www.proteinatlas.org/learn/cellines
http://capcelllines.ca/details.asp?id=37
http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/p/cell-lines-detail-96.html
http://tcpaportal.org/mclp/
Publications

PubMed=447482
Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W.
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
Invest. Urol. 17:16-23(1979)

PubMed=6244232
Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=8104329; DOI=10.1002/pros.2990230206
Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P.
p53 oncogene mutations in three human prostate cancer cell lines.
Prostate 23:123-134(1993)

PubMed=8687134
Pandalai P.K., Pilat M.J., Yamazaki K., Naik H., Pienta K.J.
The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth.
Anticancer Res. 16:815-820(1996)

PubMed=9018337; DOI=10.1002/(SICI)1097-0045(19970101)30:1<58::AID-PROS9>3.0.CO;2-H
Webber M.M., Bello D., Quader S.T.
Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines.
Prostate 30:58-64(1997)

PubMed=10702678; DOI=10.1159/000015432
Pan Y., Kytola S., Farnebo F., Wang N., Lui W.-O., Nupponen N., Isola J., Visakorpi T., Bergerheim U.S.R., Larsson C.
Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping.
Cytogenet. Cell Genet. 87:225-232(1999)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., Van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=10754530; DOI=10.1002/(SICI)1097-0045(20000501)43:2<144::AID-PROS9>3.0.CO;2-H
Suzuki Y., Kondo Y., Himeno S., Nemoto K., Akimoto M., Imura N.
Role of antioxidant systems in human androgen-independent prostate cancer cells.
Prostate 43:144-149(2000)

PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H
Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Mol. Carcinog. 28:236-246(2000)

PubMed=11135431; DOI=10.1002/1098-2264(2000)9999:9999<::AID-GCC1076>3.0.CO;2-E
Aurich-Costa J., Vannier A., Gregoire E., Nowak F., Cherif D.
IPM-FISH, a new M-FISH approach using IRS-PCR painting probes: application to the analysis of seven human prostate cell lines.
Genes Chromosomes Cancer 30:143-160(2001)

PubMed=11172901; DOI=10.1016/S0165-4608(00)00339-3
Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D.
The use of multicolor fluorescence technologies in the characterization of prostate carcinoma cell lines: a comparison of multiplex fluorescence in situ hybridization and spectral karyotyping data.
Cancer Genet. Cytogenet. 124:112-121(2001)

PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=12725112; DOI=10.1385/1-59259-372-0:21
Russell P.J., Kingsley E.A.
Human prostate cancer cell lines.
Methods Mol. Med. 81:21-39(2003)

PubMed=14518029; DOI=10.1002/pros.10290
van Bokhoven A., Varella-Garcia M., Korch C., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.
Molecular characterization of human prostate carcinoma cell lines.
Prostate 57:205-225(2003)

PubMed=15486987; DOI=10.1002/pros.20158
Zhao H., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R., Brooks J.D.
Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.
Prostate 63:187-197(2005)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001
Azari S., Ahmadi N., Tehrani M.J., Shokri F.
Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
Biologicals 35:195-202(2007)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

DOI=10.4172/2157-7145.S2-005
Fang R., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=21432867; DOI=10.1002/pros.21383
Tai S., Sun Y., Squires J.M., Zhang H., Oh W.-K., Liang C.-Z., Huang J.
PC3 is a cell line characteristic of prostatic small cell carcinoma.
Prostate 71:1668-1679(2011)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L., Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20-20(2013)

PubMed=24504141; DOI=10.3892/ijo.2014.2287
Suetens A., Moreels M., Quintens R., Chiriotti S., Tabury K., Michaux A., Gregoire V., Baatout S.
Carbon ion irradiation of the human prostate cancer cell line PC3: a whole genome microarray study.
Int. J. Oncol. 44:1056-1072(2014)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26256267; DOI=10.1074/mcp.M115.047928
Shah P., Wang X., Yang W., Toghi Eshghi S., Sun S., Hoti N., Chen L., Yang S., Pasay J., Rubin A., Zhang H.
Integrated proteomic and glycoproteomic analyses of prostate cancer cells reveal glycoprotein alteration in protein abundance and glycosylation.
Mol. Cell. Proteomics 14:2753-2763(2015)

PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
J. Proteomics 139:77-83(2016)

PubMed=27141528; DOI=10.1016/j.dib.2016.04.001
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Data Brief 7:1302-1305(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20-20(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections AddexBio; C0019002/61
ATCC; CRL-1435
ATCC; CRL-7934 - Discontinued
BCRC; 60122
BCRJ; 0269
CLS; 300312/p1699_PC-3
DSMZ; ACC-465
ECACC; 90112714
ICLC; HTL97018
IZSLER; BS TCL 175
JCRB; JCRB9110
KCB; KCB 200725YJ
KCLB; 21435
NCBI_Iran; C427
NCI-DTP; PC-3
RCB; RCB2145
TKG; TKG 0600
Cell line databases/resources CLDB; cl3881
CLDB; cl3883
CCLE; PC3_PROSTATE
CCRID; 3111C0001CCC000115
CCRID; 3131C0001000700041
CCRID; 3131C0001000700158
CCRID; 3142C0001000000113
Cosmic-CLP; 905934
GDSC; 905934
LINCS_HMS; 50454
LINCS_LDP; LCL-1299
SKY/M-FISH/CGH; 2799
TOKU-E; 2868
Ontologies BTO; BTO:0001061
CLO; CLO_0008395
CLO; CLO_0051535
EFO; EFO_0002074
MCCL; MCC:0000380
Biological sample resources BioSample; SAMN01821588
BioSample; SAMN01821653
BioSample; SAMN01821713
BioSample; SAMN03472063
ENCODE; ENCBS420VDY
ENCODE; ENCBS451OVM
ENCODE; ENCBS504WVV
ENCODE; ENCBS596CTT
ENCODE; ENCBS608AAA
ENCODE; ENCBS609AAA
Chemistry resources ChEMBL-Cells; CHEMBL3307570
ChEMBL-Targets; CHEMBL390
Gene expression databases GEO; GSM2171
GEO; GSM50225
GEO; GSM50289
GEO; GSM91930
GEO; GSM142459
GEO; GSM142460
GEO; GSM482670
GEO; GSM525804
GEO; GSM595615
GEO; GSM648823
GEO; GSM750835
GEO; GSM784792
GEO; GSM799370
GEO; GSM799433
GEO; GSM847110
GEO; GSM844675
GEO; GSM844674
GEO; GSM887506
GEO; GSM888588
GEO; GSM1153442
GEO; GSM1181274
GEO; GSM1181303
GEO; GSM1374817
GEO; GSM1374818
GEO; GSM1670339
GEO; GSM2124647
Other Wikidata; Q7118483
Polymorphism and mutation databases Cosmic; 688118
Cosmic; 704849
Cosmic; 713868
Cosmic; 719680
Cosmic; 721366
Cosmic; 721556
Cosmic; 755297
Cosmic; 759894
Cosmic; 801350
Cosmic; 809225
Cosmic; 850414
Cosmic; 869157
Cosmic; 873002
Cosmic; 875892
Cosmic; 876396
Cosmic; 897455
Cosmic; 905934
Cosmic; 911997
Cosmic; 918502
Cosmic; 920968
Cosmic; 921048
Cosmic; 922551
Cosmic; 923957
Cosmic; 943175
Cosmic; 948379
Cosmic; 949249
Cosmic; 974299
Cosmic; 1028650
Cosmic; 1028702
Cosmic; 1071477
Cosmic; 1075273
Cosmic; 1092627
Cosmic; 1172628
Cosmic; 1175888
Cosmic; 1188436
Cosmic; 1212489
Cosmic; 1219448
Cosmic; 1305380
Cosmic; 1312367
Cosmic; 1330910
Cosmic; 1436048
Cosmic; 1689714
Cosmic; 1995613
Cosmic; 1998469
Cosmic; 2301588
Cosmic; 2580130
Cosmic; 2585153
Cosmic; 2585230
Proteomic databases PRIDE; PRD000228
PRIDE; PRD000597
PRIDE; PXD002107
PRIDE; PXD003105